Buscar
United Therapeutics Corp
UTHRAñadir a la lista de seguimiento
544.330USD
+6.030+1.12%
Cierre 06/23, 16:00（ET）Cotizaciones retrasadas 15 min
22.95BCap. mercado
18.60P/E TTM
Más Datos de United Therapeutics Corp Compañía
United Therapeutics Corporation is a pharmaceutical company. The Company markets and sells commercial therapies to treat pulmonary arterial hypertension (PAH): Tyvaso DPI (treprostinil) Inhalation Powder (Tyvaso DPI); Tyvaso (treprostinil) Inhalation Solution (nebulized Tyvaso), which includes the Tyvaso Inhalation System; Remodulin (treprostinil) Injection (Remodulin); Orenitram (treprostinil) Extended-Release Tablets (Orenitram); and Adcirca (tadalafil) Tablets (Adcirca). Tyvaso DPI and nebulized Tyvaso are also approved to treat pulmonary hypertension associated with interstitial lung disease (PH-ILD). It also markets and sells an oncology product, Unituxin (dinutuximab) Injection for the treatment of high-risk neuroblastoma, and the Remunity Pump for Remodulin. Tyvaso DPI is a drug-device combination product that incorporates the dry powder formulation technology and Dreamboat inhalation device technology used in MannKind’s Afrezza (insulin human) Inhalation Powder product.
Información de United Therapeutics Corp
Símbolo de cotizaciónUTHR
Nombre de la empresaUnited Therapeutics Corp
Fecha de salida a bolsaJun 17, 1999
Director ejecutivoRothblatt (Martine A)
Número de empleados1305
Tipo de seguridadOrdinary Share
Fin del año fiscalJun 17
Dirección1000 Spring St
CiudadSILVER SPRING
Bolsa de valoresNASDAQ OMX - NASDAQ BASIC
PaísUnited States of America
Código postal20910
Teléfono13016089292
Sitio Webhttps://www.unither.com/
Símbolo de cotizaciónUTHR
Fecha de salida a bolsaJun 17, 1999
Director ejecutivoRothblatt (Martine A)
Ejecutivos de United Therapeutics Corp
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Martine A. Rothblatt
Dr. Martine A. Rothblatt
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
701.73K
--
Mr. Paul A. Mahon, J.D.
Mr. Paul A. Mahon, J.D.
Executive Vice President, General Counsel, Corporate Secretary
Executive Vice President, General Counsel, Corporate Secretary
45.17K
--
Mr. Michael Benkowitz
Mr. Michael Benkowitz
President, Chief Operating Officer
President, Chief Operating Officer
21.39K
+87.62%
Mr. Richard A. Giltner
Mr. Richard A. Giltner
Independent Director
Independent Director
20.57K
--
Prof. Nilda Mesa, J.D.
Prof. Nilda Mesa, J.D.
Independent Director
Independent Director
5.03K
-5.13%
The Hon. Dr. Louis W. Sullivan, M.D.
The Hon. Dr. Louis W. Sullivan, M.D.
Independent Director
Independent Director
3.79K
+15.57%
Mr. Christopher Patusky, J.D.
Mr. Christopher Patusky, J.D.
Lead Independent Vice Chairman of the Board
Lead Independent Vice Chairman of the Board
2.59K
--
Ms. Jan Malcolm
Ms. Jan Malcolm
Director
Director
125.00
--
Mr. Raymond C. (Ray) Kurzweil, J.D.
Mr. Raymond C. (Ray) Kurzweil, J.D.
Independent Director
Independent Director
--
--
Mr. Christopher A. Causey
Mr. Christopher A. Causey
Independent Director
Independent Director
--
--
Ver más
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Martine A. Rothblatt
Dr. Martine A. Rothblatt
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
701.73K
--
Mr. Paul A. Mahon, J.D.
Mr. Paul A. Mahon, J.D.
Executive Vice President, General Counsel, Corporate Secretary
Executive Vice President, General Counsel, Corporate Secretary
45.17K
--
Mr. Michael Benkowitz
Mr. Michael Benkowitz
President, Chief Operating Officer
President, Chief Operating Officer
21.39K
+87.62%
Mr. Richard A. Giltner
Mr. Richard A. Giltner
Independent Director
Independent Director
20.57K
--
Prof. Nilda Mesa, J.D.
Prof. Nilda Mesa, J.D.
Independent Director
Independent Director
5.03K
-5.13%
The Hon. Dr. Louis W. Sullivan, M.D.
The Hon. Dr. Louis W. Sullivan, M.D.
Independent Director
Independent Director
3.79K
+15.57%
Preguntas frecuentes
¿Quiénes son los cinco principales accionistas de United Therapeutics Corp?
Los cinco principales accionistas de United Therapeutics Corp son: Dr. Martine A. Rothblatt
¿Cuántas instituciones poseen acciones de United Therapeutics Corp (UTHR)?
A fecha de 2026Q1, 1548 instituciones poseen acciones de United Therapeutics Corp, con un valor de mercado combinado de aproximadamente 42.91M, lo que representa el 101.10% del total de acciones. En comparación con el 2025Q4, el accionariado institucional ha aumentado en -1413631.00.
¿Cuál es la mayor fuente de ganancias de United Therapeutics Corp?
El 2026Q1, el segmento empresarial Tyvaso DPI generó la ganancia más alta para United Therapeutics Corp, ascendiendo a 1.29B y representando el 40.59% de la ganancia total.
